|
|
|
Volumn 23, Issue 5 SUPPL. 10, 1996, Pages 90-98
|
|
Economic value of gemcitabine in non-small cell lung cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIEMETIC AGENT;
CISPLATIN;
ETOPOSIDE;
GEMCITABINE;
IFOSFAMIDE;
NUCLEOSIDE ANALOG;
BONE MARROW SUPPRESSION;
CANCER SURVIVAL;
CHEMOTHERAPY;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
EDEMA;
GASTROINTESTINAL SYMPTOM;
GERMANY;
HEALTH CARE COST;
HEALTH ECONOMICS;
HEALTH SERVICE;
HOSPITALIZATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
MODEL;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REVIEW;
SPAIN;
UNITED STATES;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
DEOXYCYTIDINE;
HEALTH CARE COSTS;
HUMANS;
LUNG NEOPLASMS;
|
|
EID: 0029808877
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (17)
|
|
References (0)
|
